Company / R&D Expense
Cogent Biosciences, Inc. R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$269.8M
FY2025
5-year range
$55.9M / $269.8M
FY2021-FY2025
Trend
+16.0%
vs FY2024
Sector context
#67 of 210
Health Care
What the data says
At $270M, Cogent Biosciences, Inc.'s r&d expense ranks #67 of 210 in the Health Care sector. R&D Expense has increased for 5 consecutive years, from $26M in FY2020 to $270M in FY2025.
Based on SEC 10-K filings.
$270M in FY2025 with a 5-year CAGR of +60.0%.
Improved from $174M to $270M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +30.4%
- 5-Year CAGR
- +60.0%
- 10-Year CAGR
- -
Sector benchmark
#67 of 210 in Health CareTop 32% of 210This company $269.8M Sector average $644.1M
▼
-58.1% below sector average
Key checks
Key Insights
- Cogent Biosciences, Inc.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +60.0%, indicating consistent growth.
- In FY2025, r&d expense increased 16.0% year-over-year.
- Ranks #67 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $269.8M | +16.0% |
| FY2024 | $232.7M | +33.9% |
| FY2023 | $173.8M | +42.9% |
| FY2022 | $121.6M | +117.5% |
| FY2021 | $55.9M | +117.2% |
| FY2020 | $25.7M | -41.1% |
| FY2019 | $43.7M | +14.2% |
| FY2018 | $38.3M | +28.3% |
| FY2017 | $29.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026